Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of LBL-034 in Patients With Relapsed/Refractory Multiple Myeloma

NCT06049290 is registered in ClinicalTrials.gov with Nanjing Leads Biolabs Co.,Ltd as lead sponsor.

NCT NCT06049290
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06049290 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of LBL-034 in Patients With Relapsed/Refractory Multiple Myeloma
Lead sponsor
Nanjing Leads Biolabs Co.,Ltd
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 20, 2023
Completion date
May 20, 2027
Enrollment
342 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory multiple myeloma